How belimumab changes lupus over time
Part of Immune system & allergy, Skin clinical trials.
This study looks at how the drug belimumab affects the long-term course of lupus. It compares patients who receive belimumab to similar patients who do not, to see if it helps control disease activity over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have been diagnosed with lupus using the SLICC criteria
- You have been seen by your doctor for lupus for at least 6 months
- Your lupus is currently active (SLEDAI-2K score of 4 or higher)
- You do not have another autoimmune disease, except for thyroid disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a drug called belantamab mafodotin to the usual lupus treatments can help reduce disease activity and lower a specific antibody in the blood (anti-dsDNA). It is for people with moderate to severe lupus who have not had good results with previous medications.
This study looks at how well belimumab works in people with systemic lupus erythematosus (SLE), a condition where the immune system attacks the body. It aims to see if the treatment helps, regardless of how well it worked in the past.
This trial tests belimumab to see if it can improve lupus (SLE) disease activity in people who were diagnosed within the last two years. You may be eligible if your lupus is currently mild to moderate and your background lupus medicines are stable.
This study looks at how well belimumab (Benlysta) works in real-world settings for adults with lupus nephritis (kidney inflammation caused by lupus). If you started belimumab in the past 6–24 months, the researchers will review your medical records to see how your kidney health has changed.
This study tests the long-term safety and effectiveness of belimumab for people with lung scarring caused by scleroderma or other connective tissue diseases. It is for patients who already completed a one-year study with belimumab and were not considered treatment failures.
This trial compares two medications, telitacicept and belimumab, to see which is safer and more effective for treating lupus. It might help you if standard treatments haven't worked well for you.
Hear when a new SLE - Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.